Zealand Pharma, a Denmark-based drugmaker, will acquire “substantially all” of Valeritas’ assets for $23 million, according to a Feb. 9 news release.
Valeritas manufactures the V-Go wearable insulin delivery device.
The company said it will continue operations as normal during the transaction with Zealand.
Read the full news release here.
More articles on supply chain:
Coronavirus will cost Boston Scientific $10M to $40M in Q1, company says
Premier acquires New York Hospital Association’s GPO
Tennessee hospital lab manager quits, says hospital regularly ran out of critical supplies
